We will not undertake our initial business combination with any company based in or having the majority of the company’s operations in China, including Hong Kong and Macau. (Incorporated in Delaware) We intend to focus our search on technology-enabled sectors in North America, including but not limited to the e-commerce, financial services, educational technology services or […]

We intend to acquire companies with enterprise values of between $150 million and $300 million that are preferably already revenue-generating. We believe we have greater access to companies within this range and the negotiation process is generally less time consuming than companies that are much larger. (Incorporated in the Cayman Islands) **Note: From the prospectus: “As a Cayman Islands company […]

We will primarily seek to acquire one or more growth businesses with a total enterprise value of between $200 million and $400 million. (Incorporated in the Cayman Islands) We will seek to capitalize on the strength of our management team. Our team consists of experienced professionals and senior operating executives. Collectively, our officers and directors […]

We intend to focus on middle-market businesses with a total enterprise value of between $300 million and $500 million. We will search for companies in business segments with strategic significance to the Asian markets. Such sectors include the Internet and high tech, financial technology (FinTech), clean energy, agriculture machinery, health care, consumer and retail, energy […]

(Note: This IPO is a unit offering. Each unit consists of one share of common stock and one warrant to buy one share of stock. Heart Test Laboratories, Inc. has applied to the NASDAQ to list its stock under the proposed symbol “HSCS” and the warrant under the proposed symbol “HSCSW”. We are doing business […]

We are developing synthetic human hearts using 3D bioprinting technology. We are still in the research and development stage. Our key research focus is currently on the development of a functional mini-heart that can be utilized for cardiotoxicity testing. Continued development relating to our other potential commercialization opportunities we are planning, including cardiac valves, patches, […]

(Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTCQB, where NeoVolta’s stock trades under the symbol “NEOV”. **This is also a unit offering. Each unit consists of one share of common stock and one warrant to buy one share of common stock, exercisable at the IPO price. IPOScoop has NO […]

(Note: This IPO is a unit offering. Each unit consists of one share of common stock and one warrant to buy one share of common stock. This is a NASDAQ listing.) Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development- stage specialty pharmaceutical company focused […]

We intend to focus our search for a target business on a technology company that is driving its growth in the electric vehicle (“EV”) and urban “smart” mobility industry that may include businesses adjacent thereto in the sustainable transportation and related ecosystem, which complement our management team’s backgrounds. (Incorporated in Delaware) With technology taking the […]

(Note: Glucose Health, Inc. withdrew its plans for a NASDAQ uplisting in an SEC letter dated June 28, 2023.) (Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTC Markets. Glucose Health, Inc. filed an S-1/A on Jan. 9, 2023, in which it revamped its uplisting by switching to the NASDAQ […]